A proof-of-mechanism study reported on activation of the P53 pathway and subsequent decreased tumor cell proliferation when patients with a resectable MDM2-amplified WD- and DD-LPS were treated with RG7112, a small molecule MDM2-antagonist, in a neoadjuvant setting (window of opportunity) [20]. The gene discussed is TP53; the disease is neoplasm.